BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32074277)

  • 1. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
    Maziarz RT; Waller EK; Jaeger U; Fleury I; McGuirk J; Holte H; Jaglowski S; Schuster SJ; Bishop MR; Westin JR; Mielke S; Teshima T; Bachanova V; Foley SR; Borchmann P; Salles GA; Zhang J; Tiwari R; Pacaud LB; Ma Q; Tam CS
    Blood Adv; 2020 Feb; 4(4):629-637. PubMed ID: 32074277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.
    Goto H; Makita S; Kato K; Tokushige K; Fujita T; Akashi K; Izutsu K; Teshima T
    Int J Clin Oncol; 2020 Sep; 25(9):1736-1743. PubMed ID: 32448949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
    Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
    Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.
    Bishop MR; Maziarz RT; Waller EK; Jäger U; Westin JR; McGuirk JP; Fleury I; Holte H; Borchmann P; Del Corral C; Tiwari R; Anak Ö; Awasthi R; Pacaud L; Romanov VV; Schuster SJ
    Blood Adv; 2019 Jul; 3(14):2230-2236. PubMed ID: 31332046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
    Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
    Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
    Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
    Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
    N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
    Thudium Mueller K; Grupp SA; Maude SL; Levine JE; Pulsipher MA; Boyer MW; August KJ; Myers GD; Tam CS; Jaeger U; Foley SR; Borchmann P; Schuster SJ; Waller EK; Awasthi R; Potthoff B; Warren A; Waldron ER; McBlane F; Chassot-Agostinho A; Laetsch TW
    Blood Adv; 2021 Dec; 5(23):4980-4991. PubMed ID: 34432863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
    Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
    J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
    [No Abstract]   [Full Text] [Related]  

  • 11. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma.
    Maziarz RT; Zhang J; Yang H; Chai X; Yuan C; Schwarz E; Jakovac M; Martinez-Prieto M; Agarwal A; Degtyarev E; Tam C; Salles G
    Blood Adv; 2022 Apr; 6(8):2536-2547. PubMed ID: 35030634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
    Awasthi R; Pacaud L; Waldron E; Tam CS; Jäger U; Borchmann P; Jaglowski S; Foley SR; van Besien K; Wagner-Johnston ND; Kersten MJ; Schuster SJ; Salles G; Maziarz RT; Anak Ö; Del Corral C; Chu J; Gershgorin I; Pruteanu-Malinici I; Chakraborty A; Mueller KT; Waller EK
    Blood Adv; 2020 Feb; 4(3):560-572. PubMed ID: 32045475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
    Cher BP; Gan KY; Aziz MIA; Lin L; Hwang WYK; Poon LM; Ng K
    J Med Econ; 2020 Nov; 23(11):1321-1329. PubMed ID: 32780608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
    Shah J; Shacham S; Kauffman M; Daniele P; Tomaras D; Tremblay G; Casasnovas RO; Maerevoet M; Zijlstra J; Follows G; P Vermaat JS; Kalakonda N; Goy AH; Choquet S; Den Neste EV; Hill BT; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Bouabdallah R; Jäger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vasilakopoulos TP; Samal P; Nagy A; Ku M; Canales Albendea MÁ
    Future Oncol; 2021 Apr; 17(11):1295-1310. PubMed ID: 33528286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.
    Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
    Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
    Iacoboni G; Villacampa G; Martinez-Cibrian N; Bailén R; Lopez Corral L; Sanchez JM; Guerreiro M; Caballero AC; Mussetti A; Sancho JM; Hernani R; Abrisqueta P; Solano C; Sureda A; Briones J; Martin Garcia-Sancho A; Kwon M; Reguera-Ortega JL; Barba P;
    Cancer Med; 2021 May; 10(10):3214-3223. PubMed ID: 33932100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.
    Wang XJ; Wang YH; Li SCT; Gkitzia C; Lim ST; Koh LP; Lim FLWI; Hwang WYK
    J Med Econ; 2021; 24(1):637-653. PubMed ID: 33904359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results.
    Jaeger U; Worel N; McGuirk JP; Riedell PA; Fleury I; Du Y; Han X; Pearson D; Redondo S; Waller EK
    Blood Adv; 2023 Jun; 7(11):2283-2286. PubMed ID: 36044388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Spira A; Zhou X; Chen L; Gnanasakthy A; Wang L; Ungar D; Curiel R; Liao L; Radford J; Kahl B
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):158-168. PubMed ID: 34690090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.